FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings for FibroGen, Inc. (FGEN)
Earnings in 2023 (TTM): $-286,867,000
According to FibroGen, Inc.'s latest financial reports the company's current earnings (TTM) are $-286,867,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of FibroGen, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-286,867,000 | $-284,232,000 |
| 2022 | $-294,869,000 | $-295,227,000 |
| 2021 | $-290,683,000 | $-291,030,000 |
| 2020 | $-188,931,000 | $-189,291,000 |
| 2019 | $-76,642,000 | $-76,970,000 |
| 2018 | $-86,116,000 | $-86,420,000 |
| 2017 | $-125,882,000 | $-126,203,000 |
| 2016 | $-61,751,000 | $-61,680,000 |
| 2015 | $-85,537,000 | $-85,779,000 |
| 2014 | $-59,504,000 | $-59,504,000 |
| 2013 | $-14,943,000 | $-14,943,000 |
| 2012 | $-32,671,000 | $-32,571,000 |